Loading...
  • patients
  • Determine the maximum tolerated dose of metronomic docetaxel in patients with progressive or recurrent gynecologic cancer. (clinicaltrials.gov)
  • Patients must have histologically confirmed advanced, refractory gynecologic cancer. (clinicaltrials.gov)
  • RATIONALE: Gathering information from patients who have undergone treatment for upper gastrointestinal cancer or gynecological cancer may help doctors learn more about patients' physical and psychosocial rehabilitation needs and plan the best treatment. (clinicaltrials.gov)
  • PURPOSE: This clinical trial is studying the physical and psychosocial rehabilitation needs of patients after diagnosis and treatment of upper gastrointestinal cancer or gynecological cancer. (clinicaltrials.gov)
  • To explore the patients' perspective of their physical and psychosocial rehabilitation needs following the diagnosis and treatment for an upper gastrointestinal or a gynecological cancer. (clinicaltrials.gov)
  • To assess patients' experiences of the physical and social impact of cancer in the treatment and post-treatment phase. (clinicaltrials.gov)
  • Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding cancer treatments and sexuality delivered over two sessions. (clinicaltrials.gov)
  • PURPOSE: This phase I trial is studying the side effects and best dose of topotecan in treating patients with gynecologic cancer that cannot be removed by surgery. (clinicaltrials.gov)
  • RATIONALE: Learning about the effect of nutritional supplements on quality of life in patients receiving chemotherapy for cancer may help doctors plan the best treatment. (clinicaltrials.gov)
  • PURPOSE: This randomized phase II trial is studying nutritional supplements to see how well they work in improving quality of life during first-line chemotherapy in patients with metastatic gynecologic cancer. (clinicaltrials.gov)
  • Measure quality of life (QLQ-C30) at week 18 in patients with metastatic gynecological cancer receiving systematic nutritional supplements during first-line chemotherapy. (clinicaltrials.gov)
  • Because most cancers occur in patients who are 65 or older, the incidence of cancer is expected to increase as the population ages. (tabers.com)
  • Cancer patients may suffer depression and anxiety and have nutritional deficits. (tabers.com)
  • In vulvar cancer, the GROINS-V-II study protocol was amended to mandate inguinofemoral lymphadenectomy in all patients with SLN macrometastasis greater than 2 mm after unacceptably high rates of groin recurrences were observed on interim analysis. (springer.com)
  • One study using PDT in 9 endometrial cancer patients reported 1 complete response 12 months after treatment. (gfmer.ch)
  • Phase
  • The purpose of this phase I study is to determine the highest dose of carboplatin and gemcitabine (gemcitabine hydrochloride) that can be given safely to subjects with gynecologic cancer, in combination with stereotactic body radiation therapy (SBRT). (clinicaltrials.gov)
  • assessment
  • I. Off-study SBRT target local control assessment: 6-week post-trial fludeoxyglucose F 18 (18F-FDG) positron emission tomography (PET)/computed tomography (CT) or other imaging response by European Organisation for Research and Treatment of Cancer (EORTC) PET criteria as listed and National Cancer Institute (NCI) guidelines. (clinicaltrials.gov)
  • malignancies
  • Identification and development of highly sensitive and specific tumor markers for the detection and management of ovarian cancer and other gynecological malignancies [ Time Frame: Outcomes will be assessed at the completion of the study. (clinicaltrials.gov)
  • To identify and develop highly sensitive and specific tumor markers for the detection and management of ovarian cancer and other gynecological malignancies. (clinicaltrials.gov)
  • Ironically, chemotherapeutic drugs used to treat some cancers may damage chromosomes and occasionally cause secondary malignancies. (tabers.com)
  • recurrent
  • Participants may have samples of blood, tissue, or body fluids (such as ascites, pleural fluid or urine), or any combination of the aforementioned samples obtained to develop tumor markers to detect early stage or recurrent ovarian cancer. (clinicaltrials.gov)
  • radiation
  • Ionizing radiation, ultraviolet light, some viruses, and drugs that damage nucleic acids may initiate the genetic lesions that result in cancers. (tabers.com)
  • early stage
  • In the future, if any of the experimental tumor markers are found to be effective in detecting early stage ovarian cancer, and the patient's result is abnormal, the patient and physician will be notified. (clinicaltrials.gov)
  • abnormal
  • Usually, as cancer cells proliferate, they become increasingly abnormal and require more of the body's metabolic output for their growth and development. (tabers.com)
  • patient's
  • Does a Post Treatment Survivorship Care Plan Improve Gynaecological Cancer Patient's Quality of Life and Self Efficacy? (knowcancer.com)
  • The specific treatment used depends on the type, stage, and location of the cancer and the patient's general health. (tabers.com)
  • treatment
  • They also reported that they wanted support and information to manage consequences of cancer and treatment themselves rather than become 'overmedicalised' and require treatment from a professional, if that were possible (Sandsund et al. (knowcancer.com)
  • Americans
  • In 2013, the NCI estimated that more than 1,660,000 Americans would be diagnosed with cancer and that approx. (tabers.com)
  • Outcomes
  • Identification of measures to improve the quality of life for women at increased risk for developing the disease and for women diagnosed with ovarian cancer [ Time Frame: Outcomes will be assessed at the completion of the study. (clinicaltrials.gov)